The limited evidence suggests that IMY compared with intravenous oxytocin may result in little to no difference in the incidence of PPH and most side effects, but may reduce nausea/vomiting and the volume of blood loss slightly. This evidence concerns the gene OXT and pulmonary arterial hypertension.